ClinicalTrials.gg

Program

RSS0343

A development code. Also written as “RSS0343 Tablets”, “RSS0343 Tablet; Rifampicin Capsules” and “RSS0343 Tablet; Clarithromycin Tablets”.

In Jiangsu HengRui Medicine's pipeline, DPP1. Its studies are mostly in Bronchiectasis · Pulmonary Disease, Chronic Obstructive · Asthma, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Jan 9, 20254 company-led studies, 3 open or runningNext primary completion: Nov 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine43 open or runningphase 2since Jan 9, 2025Jan 9, 2025Nov 2027phase 2 · NCT06775340
  • Named in Jiangsu HengRui Medicine’s own pipeline as RSS0343, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 9, 2025First study: phase 2 study in Adolescent AsthmaFirst studyNCT06775340 · 252 planned · China
  2. Dec 4, 2025Phase 1 study in Non-cystic Fibrosis BronchiectasisNCT07289464 · 48 enrolled · China
  3. Jan 9, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07349524 · 300 planned · China
  4. Jul 6, 2026Phase 1 study in Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary DiseaseNCT07696091 · 40 planned · China

Ahead

  1. Nov 2027Primary completion: phase 2 study in Adolescent AsthmaNCT06775340
  2. Mar 2028Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07349524

TargetBeta

“DPP1”the company's pipeline, read by Claude · source

Other programs on CTSC

ProgramCompanyFurthest phaseStudies
verducatibBoehringer Ingelheimphase 321
brensocatibruleInsmedphase 317

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07696091Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease · China1Not yet recruitingSep 202640
NCT07349524Pulmonary Disease, Chronic Obstructive · China2RecruitingMar 2028300
NCT07289464Non-cystic Fibrosis Bronchiectasis · China1CompletedAug 10, 202648
NCT06775340Adolescent Asthma · China2RecruitingNov 2027252

How it is read

Names in the registry

  • “RSS0343 Tablets”, 1 entry
  • “RSS0343 Tablet; Rifampicin Capsules”, 1 entry
  • “RSS0343 Tablet; Clarithromycin Tablets”, 1 entry
  • “RSS0343 tablets”, 1 entry
  • “RSS0343 Tabella”, 1 entry

Codes read as this program: RSS0343.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.